Patients Receiving Coated Stents Are at Lower Risk of Death and Heart Attack

Over 700 Total Lots Up For Auction at Three Locations - NJ 03/08, MD 03/10, CA 03/12

接受上漆的Stents的患者是在死亡和心脏病发作的更低的风险

Lynn Shapiro, Writer | April 01, 2009
Coated stent
Heart disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new study supported by HHS' Agency for Healthcare Research and Quality (AHRQ) and the American College of Cardiology's National Cardiovascular Data Registry.

The comparative effectiveness study of 262,700 Medicare patients who received stents to keep heart vessels open is the largest trial ever to compare drug-coated stents with bare metal ones. It was presented on March 28 at the American College of Cardiology's 58th Annual Scientific Session in Orlando, FL.

A team of researchers from Duke University, AHRQ and Kaiser Permanente found that, compared with patients who received bare metal stents, those fitted with stents coated with medication, called drug-eluting stents, had an 18 percent better survival rate over the 30-month study period and were 16 percent less likely to suffer a heart attack.

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs

"The findings provide important new evidence for decision making by heart disease patients and their physicians," said AHRQ Director Carolyn M. Clancy, M.D. "These results should help resolve many lingering questions regarding the safety of drug-eluting stents in recent years."

HHS says FDA approved two stents coated with drugs in 2003 and 2004, but then issued precautionary advisories in 2006 after receiving scattered reports of blood clot formation, or thrombosis, and deaths. Subsequent clinical trials and other studies produced conflicting results.

The researchers in the AHRQ-funded study found that 16.5 percent of the patients implanted with bare metal stents died within 30 months of implantation, compared with 13.5 percent of those with drug-eluting stents, after adjusting for population differences. They also found that 8.9 percent of the patients with bare metal stents suffered heart attacks during the period, compared with 7.5 percent of those with drug-eluting stents--a 16 percent higher rate. The researchers further found that patients fitted with drug-eluting stents in 2005 and 2006 had a lower risk of death than those given the stents in 2004.

"Some previous studies have suggested that drug-eluting stents are associated with an excess long-term death rate, whereas others have not," said the study's lead author, Pamela S. Douglas, M.D., Geller professor of medicine at Duke University.

The researchers found no significant differences in the percentages of drug-eluting and bare metal stent patients who required a repeat angioplasty or coronary artery bypass graft surgery (roughly 23 percent) and in the percentages of patients who suffered strokes or major bleeding (about 3 percent and 3.5 percent, respectively). The results were not affected by age, gender, race, ethnicity or other factors.